Where does M3dicine IP PTY Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), M3dicine IP PTY Ltd. ranks #32,398 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does M3dicine IP PTY Ltd. hold?

M3dicine IP PTY Ltd. holds 8 US utility patents granted between 2019 and 2021, spanning 1 technology areas.

What is M3dicine IP PTY Ltd.'s Innovation Score?

M3dicine IP PTY Ltd. has an Innovation Score of 20.5 out of 100 (7th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does M3dicine IP PTY Ltd. focus on?

M3dicine IP PTY Ltd.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 6 patents, ranking #2,680 of 7,127 assignees active in that subclass. Grants appear in 1 CPC subclasses total.

Is M3dicine IP PTY Ltd.'s patent grant rate increasing or decreasing?

M3dicine IP PTY Ltd.'s recent grant velocity is +200% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for M3dicine IP PTY Ltd.'s patents?

M3dicine IP PTY Ltd.'s patents average 15.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the M3dicine IP PTY Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

M3dicine IP PTY Ltd.

USPTO PatentsView assignee record - 8 granted patents across 1 technology areas, recorded in grant years 2019–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, M3dicine ranks #32,398 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 1 technology areas.

#32,398
of 49,997 US assignees by volume: 7th percentile
by Innovation Score (20.5/100): 15.6
avg claims per patent: +200%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R32398 · Foreign Corporation #32,398 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #32,398/49,997
PHOTO-FINISH Luxer
CPC-NARROW A61B · 1 areas
INNOV-THIN 20.5/100
CLAIMS-RICH 15.6 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +200% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Luxer Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How M3dicine’s 20.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (37%) Velocity 0.0 pts (0%) Breadth 3.5 pts (17%) Claim depth 9.4 pts (46%)

Qualcomm Incorporated · highest

85
M3dicine IP PTY · this assignee

21
3D Lighting… · lowest

7

What this shows M3dicine's Innovation Score is 20.5/100 (7th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for M3dicine?

Each dot is one of M3dicine’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). M3dicine’s own 15.6 claims/patent is ABOVE the 9.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

M3dicine vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where M3dicine's grants concentrate

M3dicine IP PTY Ltd. is a focused PatentsView assignee: 1 CPC subclasses with 75% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2020 (4 grants) versus a trough of 2 in 2019. By volume, M3dicine sits between Luxer Corporation and MAF Agrobotic.

Luxer

8
M Group

8
M&M Machinery Ser…

8
M I Tech

8
MA Aluminum

8
Macbo

8
Madgrip Holdings

8
MAF Agrobotic

8
M3dicine IP PTY ◀

8

What this shows M3dicine holds 8 patents at rank #32,387, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near M3dicine

By rank, the assignees closest to #32,387 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in M3dicine's primary technology class.

M3dicine's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

21 7th percentile higher than 7% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

M3dicine IP PTY Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	2	25.0%
2020	4	50.0%
2021	2	25.0%

Which technologies does M3dicine IP PTY Ltd. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 6

Top 1 of 1 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

M3dicine IP PTY Ltd.'s patent record in context - here's where to go next.

M3dicine IP PTY Ltd.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 75% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #32,398 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare M3dicine IP PTY Ltd. against Luxer Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 20.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.